Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,826 across all filing types
Latest filing 2016-04-20 Regulatory Filings
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Genmab meddeler, at der vil blive præsenteret data vedrørende daratumumab på 2016-årsmødet i ASCO
Regulatory Filings Classification · 95% confidence The document is a 'Company Announcement' from Genmab regarding the presentation of clinical trial data (Daratumumab) at the 2016 ASCO Annual Meeting. It provides highlights of the study results and upcoming presentation details. It does not fit into specific financial reporting categories like 10-K, ER, or IR, nor is it a standalone audit or governance report. As it is a general regulatory announcement regarding company activities and clinical progress, it falls under the 'Regulatory Filings' (RNS) category.
2016-04-20 English
Genmab meddeler, at der vil blive præsenteret data vedrørende daratumumab på 2016-årsmødet i ASCO
Regulatory Filings Classification · 95% confidence The document is a corporate announcement (Selskabsmeddelelse) from Genmab regarding the upcoming presentation of clinical trial data (daratumumab) at the ASCO 2016 annual meeting. It provides highlights of the study results (Castor study) and details about the presentation schedule. It does not constitute a full financial report, audit, or proxy statement. As it is a general regulatory announcement regarding company activities and clinical progress that does not fit into more specific categories like 'Earnings Release' or 'Investor Presentation', it is classified as a Regulatory Filing (RNS).
2016-04-20 English
Earnings Release 2016
Earnings Release Classification · 100% confidence The document is titled "Selskabsmeddelelse" (Company Announcement) and its primary content is an announcement that Genmab is updating its financial guidance for 2016, driven by strong sales of DARZALEX®. It presents a table comparing the 'New expectations' versus the 'Original expectations' for Net Sales, Operating Expenses, Operating Result, and Cash position. This structure—a formal announcement updating previously issued financial outlooks—is characteristic of an Earnings Release (ER) or a general financial update. Since it is an update to guidance rather than the initial release of period-end results (which would typically be an IR or ER), and it is a formal announcement, it fits best under Earnings Release (ER) as it deals directly with updated financial performance expectations. It is not a full Annual Report (10-K) or an Interim Report (IR), nor is it merely an announcement of a report (RPA). FY 2016
2016-04-20 Danish
Earnings Release 2016
Earnings Release Classification · 100% confidence The document is titled "Company Announcement" and its primary content is the revision of the company's financial guidance for the year 2016, detailing changes in expected Revenue, Operating expenses, Operating income, and Cash position. This type of announcement, which provides key financial highlights and outlook updates outside of a full periodic report (like 10-K or IR), aligns perfectly with the definition of an Earnings Release (ER). It is not a full report (10-K or IR), nor is it a transcript (CT) or a formal audit report (AR). It is a direct release of updated financial expectations. FY 2016
2016-04-20 English
Genmab opjusterer resultatforventningerne til 2016
Earnings Release Classification · 95% confidence The document is a 'Company Announcement' from Genmab regarding an update to its financial guidance for the 2016 fiscal year. It provides specific revised figures for revenue, operating income, and cash position, explaining the drivers behind these changes (DARZALEX sales). While it contains financial data, it is an ad-hoc announcement of updated guidance rather than a full quarterly or annual report. Under the provided definitions, an initial announcement of financial results or guidance updates is classified as an Earnings Release (ER). FY 2016
2016-04-20 English
Genmab opjusterer resultatforventningerne til 2016
Earnings Release Classification · 95% confidence The document is a corporate announcement ('Selskabsmeddelelse') from Genmab regarding an upward revision of their 2016 financial guidance ('opjusterer resultatforventningerne'). It provides specific updated financial figures (revenue, operating expenses, operating profit, and cash position) and explains the drivers behind these changes (DARZALEX sales). This is a classic earnings-related guidance update, which falls under the 'Earnings Release' category as it provides the initial announcement of updated financial expectations. FY 2016
2016-04-20 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.